Search results for " OSTEOPOROSI"

showing 10 items of 110 documents

The incidence of hip, forearm, humeral, ankle, and vertebral fragility fractures in Italy: results from a 3-year multicenter study

2010

Introduction: We aimed to assess the incidence and hospitalization rate of hip and "minor" fragility fractures in the Italian population.Methods: We carried out a 3-year survey at 10 major Italian emergency departments to evaluate the hospitalization rate of hip, forearm, humeral, ankle, and vertebral fragility fractures in people 45 years or older between 2004 and 2006, both men and women. These data were compared with those recorded in the national hospitalizations database (SDO) to assess the overall incidence of fragility fractures occurring at hip and other sites, including also those events not resulting in hospital admissions.Results: We observed 29,017 fractures across 3 years, with…

Malemedicine.medical_specialtySettore MED/06 - Oncologia MedicaOsteoporosisImmunologyWristFractures BoneForearmCost of IllnessRheumatologymedicineSettore MED/33 - Malattie Apparato LocomotoreHumansImmunology and AllergyHumerusStatistics & numerical dataBoneAgedbusiness.industryhip fractures vertebral fracturesIncidence (epidemiology)Settore MED/34 - Medicina Fisica E RiabilitativaIncidenceAged; Cost of Illness; Female; Forearm Injuries; epidemiology/etiology; Fractures; Bone; Hip Injuries; Hospitalization; statistics /&/ numerical data; Humans; Humerus; injuries; Incidence; Italy; epidemiology; Male; Middle Aged; Osteoporosis; complications; Spinal Fracturesfragility fractures; osteoporosisfragility fracturesForearm InjuriesHumerusMiddle Agedmedicine.diseaseMale; Middle Aged; Hip Injuries; Humerus; Spinal Fractures; Cost of Illness; Female; Forearm Injuries; Italy; Hospitalization; Humans; Osteoporosis; Fractures Bone; Aged; IncidenceSurgeryHospitalizationmedicine.anatomical_structureItalyOrthopedic surgeryPhysical therapyOsteoporosisSpinal FracturesFemaleAnklebusinessFracturesHip InjuriesResearch ArticleArthritis Research & Therapy
researchProduct

Polymyalgia rheumatica and vertebral fractures: a 1-year pilot controlled study

2010

No data exist about the possibility that vertebral fracture in PMR patients could be independent of steroid therapy. For this reason, we aimed to investigate this topic by a case cohort study with a 1-year follow-up for each patient. We selected ten consecutive patients who experienced vertebral fractures (VF-group) during the first month of 1-year follow-up period and without any other significant associated condition. As a control group we studied ten control patients, without vertebral fractures and with a follow-up of 1 year, randomly selected among a larger group of patients affected by polymyalgia rheumatica. The following data were analysed: eritrosedimention rate (ESR), visual analo…

Malemedicine.medical_specialtyTime FactorsSettore MED/09 - Medicina Internamedicine.drug_classGiant Cell ArteritisImmunologyOsteoporosisPilot Projectslaw.inventionCohort StudiesPolymyalgia rheumaticaRheumatologyRandomized controlled triallawInternal medicinemedicineHumansImmunology and AllergyAgedPain Measurementbusiness.industryCase-control studymedicine.diseaseSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheRheumatologySurgerySettore MED/16 - ReumatologiaGiant cell arteritisTreatment OutcomePolymyalgia RheumaticaCase-Control StudiesPolymyalgia rheumatica Vertebral fractures Osteoporosis Controlled clinical trialSpinal FracturesCorticosteroidFemalebusinessFollow-Up StudiesCohort studyRheumatology International
researchProduct

BRONJ in patients with rheumatoid arthritis: A multicenter case series

2016

Objective: Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of various medications (bisphosphonates, anti-resorptive, and anti-angiogenic drugs). ONJ pathogenesis is still unclear although some risk factors have been recognized. Of these, rheumatoid arthritis (RA) has been hypothesized as a potential risk factor for developing ONJ. This observational study will describe a multicenter case series of patients affected with RA and ONJ, and it will attempt to evaluate the association between features of ONJ and pharmacological, systemic, and site variables. Methods: Demographic, pharmacological, and clinical data from 18 RA patients with ONJ were collected and registered fr…

Malemedicine.medical_specialtymedicine.medical_treatmentOsteoporosisONJArthritis Rheumatoid03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansBisphosphonateONJ; Bisphosphonate; Denosumab; Jaw; Osteonecrosis; Osteoporosis; Rheumatoid arthritis; Dentistry (all); Otorhinolaryngology2734 Pathology and Forensic MedicineRheumatoid arthritisAdverse effectGeneral DentistryRheumatoid arthritiAgedBisphosphonate-associated osteonecrosis of the jawbusiness.industryOtorhinolaryngology2734 Pathology and Forensic MedicineOsteoporosiOsteonecrosis030206 dentistryBisphosphonateMiddle Agedmedicine.diseaseSurgeryDenosumabOtorhinolaryngologyJaw030220 oncology & carcinogenesisRheumatoid arthritisOsteonecrosiDentistry (all)OsteoporosisMethotrexateBisphosphonate-Associated Osteonecrosis of the JawFemaleDenosumabbusinessOsteonecrosis of the jawmedicine.drug
researchProduct

The burden of previous fractures in hip fracture patients. The Break Study

2011

A positive history of fractures in older patients with hip fracture is common. We determined the risk factors associated with a positive history of fractures and the profile of care in hip fracture patients. In the Break Study, we enrolled 1249 women aged ≥60 years, seeking care for a hip fracture. Baseline information included age, body mass index, lifestyle (smoking habit, alcohol consumption), patient's history of fracture after the age of 50 years, family history of fragility fracture and health status (presence of comorbidity, use of specific drugs, pre-fracture walking ability, type of fracture, time to surgery, type of surgery, osteoporosis treatment). In the multivariable model age,…

Multiple fractureAgingPediatricsmedicine.medical_specialtyMultivariate analysisCross-sectional studyOsteoporosisPsychological interventionHip fractureBody Mass IndexRisk Factorship fractures; care; osteoporosismedicineHumanscareFamily historyAgedAged 80 and overHip fractureProfile of carebusiness.industrySettore MED/34 - Medicina Fisica E RiabilitativaMiddle Agedmedicine.diseaseosteoporosisComorbidityCross-Sectional StudiesHip fracture Break studyhip fracturesMultivariate AnalysisPhysical therapyFemaleGeriatrics and GerontologybusinessDelivery of Health CareBody mass indexAging Clinical and Experimental Research
researchProduct

L’odontoiatria a misura del paziente con patologia osteometabolica a rischio di osteonecrosi delle ossa mascellari da farmaci.

2016

L’osteonecrosi delle ossa mascellari (ONJ) da farmaci è una severa patologia odontoiatrica, recentemente defi nita come «una reazione avversa farmacocorrelata, caratterizzata dalla progressiva distruzione e necrosi dell’osso mandibolare e/o mascellare di soggetti esposti al trattamento con farmaci per cui sia accertato un aumentato rischio di malattia, in assenza di un pregresso trattamento radiante»1-3. I pazienti osteometabolici a rischio di sviluppare l’ONJ sono quelli sottoposti a terapia con bisfosfonati (in particolare aminobisfosfonati o Nitrogen-containing BisPhosphonate/NBP) e, più recentemente, con denosumab (anticorpo monoclonale anti-RANKL)4. Tali farmaci antiriassorbitivi carat…

ONJ osteonecrosi management osteoporosi ossa mascellari
researchProduct

Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?

2014

Guidelines for the management of osteoporosis induced by endogenous hypercortisolism are not available. Both the American College of Rheumatology and the International Osteoporosis Foundation recommend to modulate the treatment of exogenous glucocorticoid-induced osteoporosis (GIO) based on the individual fracture risk profile (calculated by FRAX) and dose of glucocorticoid used, but it is difficult to translate corticosteroid dosages to different degrees of endogenous hypercortisolism, and there are no data on validation of FRAX stratification method in patients with endogenous hypercortisolism. Consequently, it is unclear whether such recommendations may be adapted to patients with endoge…

Oncologymedicine.medical_specialtyFRAXEndocrinology Diabetes and MetabolismOsteoporosisHypercortisolismAdrenal incidentaloma; Cushing's disease; Glucocorticoids; Osteoporosis; Bone Density Conservation Agents; Cushing Syndrome; Glucocorticoids; Humans; Osteoporosis; Osteoporotic Fractures; Risk FactorsEndogenyDiseaseadrenal incidentalomaBone remodelingRisk FactorsInternal medicinemedicineHumansCushing SyndromeBone Density Conservation Agentsglucocorticoidsbusiness.industrycushing's diseaseCushing's diseasemedicine.diseaseosteoporosisRheumatologyglucocorticoids; osteoporosis; cushing's disease; adrenal incidentalomaEndocrinologyAdrenal incidentaloma; CUSHING'S DISEASE; Glucocorticoids; OsteoporosisbusinessGlucocorticoidOsteoporotic Fracturesmedicine.drug
researchProduct

Criteria for the prescription of oral bisphosphonates for the treatment of osteoporosis in a series of women referred for tooth extraction

2012

Objective: To evaluate the criteria for the prescription of oral bisphosphonates (OB) in a series of women with osteoporosis referred for tooth extraction. Study design: The study included 38 postmenopausal women on treatment with OBs. The following variables were analysed: age, weight, height, type of OB and duration of treatment, bone densitometry and risk factors for osteoporosis. In addition, the osteoporosis self-assessment tool (OST) was administered and collagen type I C-telopeptide (CTX) levels were measured. Results: Bone densitometry had only been performed in six patients (15.7%) before starting OB treatment. Based on the results of the OST, nine (23.6%) of the participants prese…

OsteoporosisDentistryAdministration OralPostmenopausal osteoporosismedicineHumansMedical prescriptionGeneral DentistryAgedCollagen typeAged 80 and overPostmenopausal womenOral bisphosphonatesDiphosphonatesbusiness.industryMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]OtorhinolaryngologyTooth ExtractionUNESCO::CIENCIAS MÉDICASOsteoporosisSurgeryResearch-ArticleFemaleOral SurgeryDensitometrybusiness
researchProduct

Osteoporosis: Economic Burden of Disease in Italy.

2020

Background and Objective: Today, osteoporosis is the most common bone disease and an important public health problem in all developed countries. The objective of this study was to estimate the costs associated with the management and treatment of osteoporosis in order to assess the economic burden in Italy for 2017, in terms of direct medical costs and social security costs. Methods: A cost of illness model was developed to estimate the average cost per year sustained by the NHS (National Health Service) and Social Security System in Italy. A systematic literature review was performed to obtain epidemiological, direct and indirect costs parameters where available. Hospitalisation costs were…

Patient Discharge.Malemedicine.medical_specialtySettore SECS-P/06accountingalliedhealth030204 cardiovascular system & hematology030226 pharmacology & pharmacyState MedicineServizio Sanitario Nazionale03 medical and health sciencesIndirect costs0302 clinical medicineCost of IllnessInternational Classification of DiseasesEnvironmental healthEpidemiologyInternational Classification of DiseasemedicineHumansPharmacology (medical)health care economics and organizationsAverage costAgedPensionbusiness.industryPublic healthOsteoporosieconomicsAged; Female; Health Care Costs; Hospitalization; Humans; International Classification of Diseases; Italy; Male; Middle Aged; Osteoporosis; Patient Discharge; State Medicine; Cost of IllnessGeneral MedicineHealth Care Costsosteoporosi Italia Servizio Sanitario NazionaleMiddle AgedItaliaPatient DischargeHealth Care CostSocial securityHospitalizationSystematic reviewItalySettore MED/42OsteoporosisFemalebusinessDeveloped countryHumanClinical drug investigation
researchProduct

Rehabilitation in a case of severe osteoporosis with prevalent fractures in a patient known with multiple sclerosis and prolonged glucocorticoid ther…

2021

Introduction. Osteoporosis has a major influence on the quality of life because of its impact on bone strength. Osteoporosis and fractures are frequent in patients with multiple sclerosis, decreased mobility being an important risk factor in these patients. Objectives. This paper presents a case of severe osteoporosis in a patient with multiple sclerosis, to emphasize a correlation between this two pathologies. Material and Methods. We present the case of a female Caucasian patient, aged 65 years, known with progressive multiple sclerosis, on long-term use of glucocorticoids, and severe osteoporosis, who is investigated for mechanical pain and functional deficiency in the lumbar spine and t…

Pediatricsmedicine.medical_specialtyRehabilitationbusiness.industryScienceMultiple sclerosismedicine.medical_treatmentQGeneral Medicinemultiple sclerosismedicine.diseaseglucocorticoid therapyosteoporosisGlucocorticoid therapymedicineSevere osteoporosisbusinessBalneo and PRM Research Journal
researchProduct

Osteoporosis risk factors in HIV positive women with osteoporosis: A retrospective analysis

2017

Multifactorial risk factors such as HIV/HCV co-infection and antiretroviral therapy (ARV) have been associated with osteoporosis in HIV+ women. We retrospectively analysed which known risk factors were associated with the diagnosis of osteoporosis, according to the WHO definition, in HIV positive women who were followed-up at the AIDS Centre of the University of Palermo, Italy between January 2011 and December 2014. Twenty-one HIV+ women with osteoporosis (13 HIV+ mono-infected and 8 HIV/HCV co-infected females) who underwent dual-energy X-ray absorptiometry (DXA) and liver stiffness assessment were included in the study. No significant differences between the HIV and HIV/HCV group were fou…

PharmacologyHIV/HCV infectedAntiretroviral therapy; HIV infected; HIV/HCV infected; Osteoporosis; Osteoporosis risk factors; Pharmacology; Drug Discovery3003 Pharmaceutical ScienceDrug Discovery3003 Pharmaceutical ScienceHIV infectedOsteoporosiOsteoporosis risk factorAntiretroviral therapy
researchProduct